GLP-1 drugs and celebrity culture: separating hype from clinical fact
Quick answer
This video contains no verifiable health claims. The transcript is rap lyric content referencing the artist Future, flagged for GLP-1 review due to the word 'shots' appearing in a non-medical context. No clinical evaluation of creator statements is possible or appropriate here.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @strictlygabe actually say?
Straightforwardly: nothing about GLP-1 medications. The transcript is rap lyrics, almost certainly from or referencing the artist Future (hence the hashtags #future and #futurehendrix). Lines like "I just feelin' with the shots, knew it came from the deep end" contain the word "shots," but context makes clear this is not a medical reference. There are no health claims here. This video was categorized under GLP-1, likely due to keyword detection picking up on "shots," but that automated flag does not hold up under a basic read of the content.
The full transcript includes lines about riding buses, stolen cars, and charges being dropped. These are standard rap narrative tropes. Attributing medical meaning to this content would require ignoring everything around the flagged word. That is not a responsible reading.
Does the science back this up?
There is no health claim to evaluate here, so this section addresses what the word "shots" actually refers to in GLP-1 medicine, since that appears to be why this video was flagged in the first place.
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are administered as subcutaneous injections, colloquially called "shots." Weekly self-administered injections are a real part of patient experience with these medications. Wilding et al. (2021, New England Journal of Medicine) established that semaglutide 2.4mg weekly produced around 15% mean body weight reduction over 68 weeks in adults with obesity. Frías et al. (2021, New England Journal of Medicine) showed tirzepatide produced up to 22.5% body weight reduction at the highest dose. These are legitimate, well-documented clinical outcomes. They have nothing to do with this video.
What did they get wrong (or right)?
The creator got nothing wrong about GLP-1 medicine because they said nothing about GLP-1 medicine. Assigning fault here would be unfair. The video is a rap performance or fan content related to the artist Future. That is entirely consistent with the hashtags used.
What is worth flagging is the broader pattern this video represents: automated content categorization systems that match single words like "shots" to medical categories will inevitably surface false positives at scale. A line like "I just feelin' with the shots" is not a dosing recommendation. It is not a testimonial. It is not a health claim of any kind. Treating it as one would be a failure of editorial judgment, not a fact-check finding.
No misinformation was spread here. No corrections are warranted for the creator.
What should you actually know?
If you landed on this fact-check because you are researching GLP-1 injections, here is what the evidence actually says. Weekly subcutaneous injections are currently the standard delivery method for semaglutide and tirzepatide. Oral semaglutide (Rybelsus) exists but shows lower bioavailability and is primarily approved for type 2 diabetes management, not weight loss at this time. Davies et al. (2017, JAMA Internal Medicine) documented that injection-related anxiety is a real barrier to GLP-1 adherence for some patients, and that clinical support during initiation improves outcomes.
Compounded versions of semaglutide have circulated widely, but the FDA has issued warnings about compounded semaglutide products. Compounded drugs are not FDA-approved and cannot be assumed equivalent to brand-name formulations in potency, purity, or safety. If you are considering any GLP-1 therapy, that conversation belongs with a licensed provider, not a TikTok comment section.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 8 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 drugs and celebrity culture: separating hype from clinical fact, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 drugs and celebrity culture: separating hype from clinical fact is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
This video contains no verifiable health claims.
FormBlends verdict
This video contains no verifiable health claims. The transcript is rap lyric content referencing the artist Future, flagged for GLP-1 review due to the word 'shots' appearing in a non-medical context. No clinical evaluation of creator statements is possible or appropriate here.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- This video contains no verifiable health claims. The transcript is rap lyric content referencing the artist Future, flagged for GLP-1 review due to the word 'shots' appearing in a non-medical context. No clinical evaluation of creator statements is possible or appropriate here.
- No GLP-1 health claims appear in this video. The content is rap lyrics referencing the artist Future.
- The word 'shots' in the transcript is a lyrical reference, not a medical one. Automated keyword matching produced a false positive here.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- No GLP-1 health claims appear in this video. The content is rap lyrics referencing the artist Future.
- The word 'shots' in the transcript is a lyrical reference, not a medical one. Automated keyword matching produced a false positive here.
- Semaglutide 2.4mg weekly produced roughly 15% mean body weight loss over 68 weeks in the STEP 1 trial (Wilding et al., 2021, NEJM).
- Tirzepatide at 15mg weekly produced up to 22.5% body weight reduction in the SURMOUNT-1 trial (Frías et al., 2021, NEJM).
- The FDA has issued warnings about compounded semaglutide. Compounded versions are not interchangeable with branded formulations.
- Injection anxiety is a documented barrier to GLP-1 adherence. Davies et al. (2017, JAMA Internal Medicine) found clinical support at initiation improves patient follow-through.
- Any decision about GLP-1 therapy should involve a licensed healthcare provider, not social media content.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
ugonis! · TikTok creator
139.9K views on this video
sensational #future #futurehendrix #fyp #ugonis
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by ugonis!, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.